MEDIPOST America

MEDIPOST America is the North American subsidiary of MEDIPOST Co., Ltd., a global leader in the development of umbilical cord blood-derived mesenchymal stem cell (UCB-MSC) therapies. The company focuses on regenerative medicine, with its lead product CARTISTEM already approved in South Korea for the treatment of knee osteoarthritis. In the United States, MEDIPOST America manages clinical development for its pipeline, which includes treatments for bronchopulmonary dysplasia and Alzheimer's disease. The company leverages its proprietary cell processing and manufacturing technologies to develop off-the-shelf allogeneic cell therapies. Its US operations are strategically located to facilitate clinical trials and business partnerships within the North American market.